Keylika
Private Company
Funding information not available
Overview
Keylika is a private, preclinical-stage biotech based in San Francisco, pioneering a combined drug discovery and delivery platform focused on metallodrugs and transdermal administration. The company's primary asset, NistuFe (KYLK01), is a novel iron complex formulated as a skin patch designed to treat iron deficiency anemia by bypassing the gastrointestinal tract, aiming to combine the efficacy of IV iron with the convenience of oral supplements. The company is founded by a team with deep expertise in material science, microsystems, and drug delivery, and is currently pre-revenue, seeking to address a significant global unmet medical need.
Technology Platform
Integrated platform combining AI-enabled de novo design of novel mixed ligand metal complexes (metallodrugs) with nanotechnology-based transdermal delivery systems and microsystems engineering for optimized drug administration.
Opportunities
Risk Factors
Competitive Landscape
Competes with established oral iron supplement makers and IV iron products (e.g., from Vifor Pharma, AMAG Pharmaceuticals, Pharmacosmos). Also faces potential competition from companies developing improved oral iron formulations (e.g., heme iron polypeptides) and subcutaneous iron injections. Keylika's differentiation is its first-in-class transdermal patch approach aiming to combine the best attributes of both existing modalities.